Allarity Therapeutics, Inc. (NASDAQ:ALLR) Short Interest Down 15.7% in April

Allarity Therapeutics, Inc. (NASDAQ:ALLR) saw a significant decline in short interest in the month of April. As of April 15th, there was short interest totaling 298,381 shares, a decline of 15.7% from the March 31st total of 353,879 shares. Approximately 1.9% of the shares of the company are sold short. Based on an average trading volume of 128,170 shares, the days-to-cover ratio is currently 2.3 days.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Private Advisor Group LLC acquired a new stake in Allarity Therapeutics during the 3rd quarter valued at approximately $441,000. Renaissance Technologies LLC increased its position in Allarity Therapeutics by 274.1% during the 4th quarter. Renaissance Technologies LLC now owns 247,612 shares of the company’s stock valued at $267,000 after purchasing an additional 181,426 shares during the period. DRW Securities LLC acquired a new stake in Allarity Therapeutics during the 4th quarter valued at approximately $133,000. Capital Advisors Inc. OK acquired a new stake in Allarity Therapeutics during the 4th quarter valued at approximately $108,000. Finally, Citadel Advisors LLC acquired a new stake in Allarity Therapeutics during the 3rd quarter valued at approximately $149,000. Institutional investors own 11.53% of the company’s stock.

Allarity Therapeutics Price Performance

Shares of NASDAQ ALLR opened at $1.30 on Friday. The company has a 50 day simple moving average of $1.17 and a 200 day simple moving average of $1.16. The firm has a market cap of $20.57 million, a PE ratio of -1.63 and a beta of 0.38. Allarity Therapeutics has a 1 year low of $0.77 and a 1 year high of $2.35.

Allarity Therapeutics (NASDAQ:ALLR) last issued its quarterly earnings data on Monday, March 30th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.01. As a group, research analysts anticipate that Allarity Therapeutics will post -0.96 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on ALLR. Ascendiant Capital Markets boosted their target price on shares of Allarity Therapeutics from $9.50 to $9.75 and gave the company a “buy” rating in a research report on Friday, April 10th. Weiss Ratings reissued a “sell (e+)” rating on shares of Allarity Therapeutics in a research report on Monday, April 20th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Allarity Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $9.75.

Allarity Therapeutics Company Profile

Allarity Therapeutics A/S (NASDAQ:ALLR) is a clinical‐stage biotechnology company focused on advancing precision medicine in oncology and other severe diseases. The company leverages predictive biomarkers and proprietary companion diagnostic tools to identify patient populations most likely to respond to its therapeutic candidates. By integrating molecular profiling early in development, Allarity aims to improve clinical trial success rates and accelerate the path to regulatory approval.

The company’s lead pipeline includes novel small‐molecule inhibitors engineered to target key pathways in solid tumors, with two primary assets currently in mid‐stage clinical trials.